KDIGO 2024 clinical practice guideline on evaluation and management of chronic kidney disease: A primer on what pharmacists need to know
American Journal of Health-System Pharmacy · 11.06.2025 · 82 (12) · 660-671
DOI: 10.1093/ajhp/zxaf044 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Health-System Pharmacy, online erschienen am 08.04.2025. Verfasst von Linda Awdishu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacy, University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA, USA. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Pharmacists, Practice Guidelines as Topic, Disease Management. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
To review the key updates in the 2024 KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease (CKD) and highlight the essential role of pharmacists in implementing these recommendations. Summary The updated guideline introduces significant changes in CKD management, including the use of validated equations for estimating glomerular filtration rate (GFR) for drug dosing, with incorporation of serum cystatin C into GFR estimates for specific patient populations, and an emphasis on a comprehensive approach to delay disease progression. The guideline recommends sodium-glucose cotransporter 2 inhibitor (SGLT2i) therapy for kidney disease with proteinuria, with or without diabetes, renin-angiotensin-aldosterone system inhibitors (RAASi) blood pressure control and proteinuria management, and statins to reduce the risk of atherosclerotic cardiovascular disease. New evidence supports the use of finerenone in patients with type 2 diabetes and CKD, and GLP-1 receptor agonists for their kidney-protective effects. The guidelines also emphasize the importance of nephrotoxin stewardship and prevention of acute kidney injury through patient education on sick day medication management.
Conclusion
Pharmacists play a crucial role in implementing these updated guidelines through comprehensive medication management, nephrotoxin stewardship, drug dosing adjustments, and patient education. Their involvement in interprofessional care teams is essential for optimizing health outcomes in patients with CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Clinical Pharmacy, University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA, USA.
- Harrison College of Pharmacy, Auburn University, Auburn, AL, USA.
- CVS Pharmacy, Inc., San Diego, CA, USA.
- Division of Nephrology, University of California, San Diego School of Medicine, La Jolla, CA, USA.
- Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada, and University Health Network, Toronto, ON, Canada.
Zitieren
APA
Awdishu, L., Maxson, R., Gratt, C., Rubenzik, T., & Battistella, M. (2025). KDIGO 2024 clinical practice guideline on evaluation and management of chronic kidney disease: A primer on what pharmacists need to know. American Journal of Health-System Pharmacy, 82(12), 660-671. https://doi.org/10.1093/ajhp/zxaf044
Vancouver
Awdishu L, Maxson R, Gratt C, Rubenzik T, Battistella M. KDIGO 2024 clinical practice guideline on evaluation and management of chronic kidney disease: A primer on what pharmacists need to know. American Journal of Health-System Pharmacy. 2025;82(12):660-671. doi:10.1093/ajhp/zxaf044
BibTeX
@article{Awdishu2025,
author = {Awdishu, Linda and Maxson, Rebecca and Gratt, Chelsea and Rubenzik, Tamara and Battistella, Marisa},
title = {KDIGO 2024 clinical practice guideline on evaluation and management of chronic kidney disease: A primer on what pharmacists need to know},
journal = {American Journal of Health-System Pharmacy},
year = {2025},
volume = {82},
number = {12},
pages = {660--671},
doi = {10.1093/ajhp/zxaf044}
}
EUVIMED